Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL612389 Target Snapshot

Streptococcus sp. 'group A' · ORGANISM · Streptococcus sp. 'group A'

Back to Search Search this target Browse approvals Evidence Card
3,250Compounds
34Assays
32Approved Drugs
3,219.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Streptococcus sp. 'group A' as ChEMBL target CHEMBL612389. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Streptococcus sp. 'group A'
ORGANISM · Streptococcus sp. 'group A'
As of 2026-09-13
ChEMBL target ID
CHEMBL612389
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Streptococcus sp. 'group A' still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameStreptococcus sp. 'group A'
Target TypeORGANISM
OrganismStreptococcus sp. 'group A'
ChEMBL ↗ NCBI Taxonomy ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelStreptococcus sp. 'group A'
UniProt AccessionN/A

Streptococcus sp. 'group A'

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Streptococcus sp. 'group A'.

Review nameStreptococcus sp. 'group A'
OrganismStreptococcus sp. 'group A'
Clinical Profile

Clinical Phase Distribution

32
Approved
2
Phase III
11
Phase II
Assay Mix

Activity Type Distribution

EC503,219.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1452261 7.2 EC50 63.0 Preclinical
CHEMBL1350780 7.17 EC50 68.0 Preclinical
CHEMBL1463750 7.17 EC50 67.0 Preclinical
CHEMBL1376248 7.16 EC50 69.0 Preclinical
CHEMBL1431875 7.14 EC50 72.0 Preclinical
CHEMBL1517362 7.14 EC50 72.0 Preclinical
CHEMBL1456111 7.13 EC50 74.0 Preclinical
CHEMBL1525098 7.13 EC50 74.0 Preclinical
CHEMBL1545940 7.11 EC50 78.0 Preclinical
CHEMBL287542 7.1 EC50 80.0 Clinical
Distribution

pChEMBL Value Distribution

1150
5.0
778
5.5
243
6.0
71
6.5
19
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

LINEZOLID
CHEMBL126
Approved 2000
Properties Compare Identifier
MOXIFLOXACIN HYDROCHLORIDE
CHEMBL1200735
Approved 1999
Properties Compare Identifier
GATIFLOXACIN
CHEMBL31
Approved 1999
Properties Compare Identifier
MEROPENEM
CHEMBL127
Approved 1996
Properties Compare Identifier
ZAFIRLUKAST
CHEMBL603
Approved 1996
Properties Compare Identifier
CEFPODOXIME PROXETIL
CHEMBL1201016
Approved 1992
Properties Compare Identifier
METHACYCLINE HYDROCHLORIDE
CHEMBL2146123
Approved 1982
Properties Compare Identifier
PIPERACILLIN SODIUM
CHEMBL1200820
Approved 1981
Properties Compare Identifier
CEFACLOR ANHYDROUS
CHEMBL680
Approved 1979
Properties Compare Identifier
CHLOROXINE
CHEMBL1200596
Approved 1976
Properties Compare Identifier
DOXORUBICIN HYDROCHLORIDE
CHEMBL359744
Approved 1974
Properties Compare Identifier
FLOXURIDINE
CHEMBL917
Approved 1970
Properties Compare Identifier
HEXACHLOROPHENE
CHEMBL496
Approved 1949
Properties Compare Identifier
Assay Landscape

Assay Landscape

34
Total Assays
2,823
Tested Compounds
1
Assay Types
Functional — 34 assays, 2,823 compounds
BAO Format Assays Compounds Avg pChEMBL
organism-based format 34 2,823 5.4

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine